Premier Alternatives

Vitrivax

Discovery Tools (Healthcare) · Boulder, CO · Founded 2014 · Privately Held (backing)

Developer of thermostable vaccine formulations designed to eliminate barriers to global vaccination. Vitrivax is based in Boulder, CO and was founded in 2014. It was valued at $69.4 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $38.2 million across 1 recorded round; the latest was a $29.4 million Series B in Nov 2025.

PMV mark · valuation
$69.4M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$38.2M
Last round
Later Stage VC (Series B)
Nov 2025

Vitrivax key facts

as of Oct 2026
  • Developer of thermostable vaccine formulations designed to eliminate barriers to global vaccination.
  • Vitrivax is valued at approximately $69.4M as of Oct 2026, set at its later-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $38.2M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($29.4M) in Nov 2025.
  • Notable investors include RA Capital Management, Gates Foundation, Fox Ventures, Colorado Office of Economic Development & International Trade, Coalition for Epidemic Preparedness Innovations — 15 tracked in total.
  • Vitrivax has filed 1 Form D with the SEC, most recently Nov 2025 ($29.4M sold to 83 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$69.4M

Valued at $69.4M at its later-stage round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Vitrivax with a free account
  • ·The complete investor list: 15 names
  • ·Watch Vitrivax: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Vitrivax funding rounds

1 rounds
Nov 2025Later Stage VC (Series B)$29.4M▮
Full funding history →

Vitrivax valuation

Vitrivax was valued at $69.4 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Vitrivax raised?

Vitrivax has raised $38.2 million in total; 1 of its rounds is on record. The largest on record was a $29.4 million Series B in Nov 2025.

Vitrivax has filed 1 Form D with the SEC, most recently in Nov 2025 ($29.4 million sold to 83 investors).

Vitrivax investors

15 investors are on record for Vitrivax, including RA Capital Management, Gates Foundation, Fox Ventures and Colorado Office of Economic Development & International Trade. The Series B in Nov 2025 drew 1 investor.

Comparable companies

Comparable discovery tools (healthcare) names by valuation on PrivateMarketView: Nature's Toolbox ($71 million), Xcell Biosciences ($65.5 million) and Algen ($24 million).

About Vitrivax

Developer of thermostable vaccine formulations designed to eliminate barriers to global vaccination. The company offers a proprietary atomic-layering thermostable antigen and adjuvant technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response, enabling users to incorporate prime doses and additional booster doses in a single-shot administration.

Industry
Discovery Tools (Healthcare)
Sector
Healthcare
HQ
Boulder, CO, United States
Founded
2014
Employees
52
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.